Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, will present three posters at the AACR-NCI-EORTC Virtual Conference from October 7-10, 2021. These presentations will cover key findings from their Phase 1b studies involving ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide for patients with metastatic prostate cancer, and the preclinical results of ORIC-114, an irreversible kinase inhibitor for HER2-positive breast cancer. A conference call to discuss the data will be held on October 7 at 9:00 a.m. ET.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced that the FDA has cleared its IND application for ORIC-533, a CD73 inhibitor, to proceed into a first-in-human clinical trial. This trial will evaluate ORIC-533 as a standalone treatment for a tumor type not previously investigated with other CD73 inhibitors. Preclinical studies show ORIC-533 has higher potency and efficacy in blocking adenosine-driven immunosuppression compared to current alternatives. The first patient is expected to be enrolled in Q4 2021. ORIC plans additional IND filings for other product candidates in the same quarter.
ORIC Pharmaceuticals will participate in several investor conferences in September 2021. Key events include a panel on targeted oncology at Citi’s 16th Annual BioPharma Virtual Conference on September 10, a company overview at the H.C. Wainwright Conference on September 13, and a fireside chat at the Oppenheimer Summit on September 22. Webcasts will be accessible on the company’s website for 90 days post-event. ORIC is developing innovative oncology treatments, including ORIC-101, targeting resistance mechanisms in cancer therapy.
ORIC Pharmaceuticals announced the appointment of Steven L. Hoerter to its Board of Directors, a move aimed at enhancing its oncology-focused strategy. Hoerter, with over 25 years of experience in the pharmaceutical industry, has previously held significant roles at companies like Genentech and Agios. His addition is expected to provide valuable guidance as ORIC advances its four oncology product candidates, including ORIC-101, which targets therapeutic resistance mechanisms in cancer. Concurrently, Peter Svennilson resigned from the board as part of a planned reduction in commitments.
ORIC Pharmaceuticals reported a strong financial position, with cash and investments totaling $305.9 million, sufficient to support operations into 2024. The company achieved significant milestones, including the clearance of the IND for ORIC-533 and the presentation of initial data for ORIC-101 at ASCO. The Phase 1 trial of ORIC-101 in prostate cancer is on track for a data readout in 2H21, and the first patient for ORIC-533 is anticipated to be dosed in the same timeframe.
ORIC Pharmaceuticals has received FDA clearance for its Investigational New Drug Application (IND) for ORIC-533, marking the initiation of its first-in-human clinical trial. This small molecule inhibitor targets CD73, aiming to combat resistance in cancer therapies. The company plans to begin a Phase 1 trial in the second half of 2021, focusing on safety and preliminary efficacy. This IND filing is part of a broader strategy, with two additional filings expected later this year. ORIC-533 shows promising preclinical results, indicating potential best-in-class capabilities.
ORIC Pharmaceuticals announced initial safety data from its Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel. The treatment was well tolerated, with mostly Grade 1 or 2 adverse events and no treatment-related discontinuations. Key findings include strong plasma concentrations and no drug-drug interaction. Notably, the treatment showed antitumor activity in heavily pretreated patients, especially those with late-line relapsed pancreatic cancer experiencing extended progression-free survival. Updated trial data is expected in 2022.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that CEO Jacob Chacko, M.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 1:30 p.m. ET. A live webcast will be accessible through the investor section of ORIC's website, with a replay available for 90 days post-event. ORIC is focused on developing cancer treatments that tackle therapeutic resistance. Their lead candidate, ORIC-101, is currently in Phase 1b trials, targeting advanced solid tumors and metastatic prostate cancer.
ORIC Pharmaceuticals has announced a conference call and webcast on June 2, 2021, at 5:00 p.m. ET to review initial data from the ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist combined with nab-paclitaxel for advanced solid tumors. The data will also be presented at the ASCO Annual Meeting from June 4-8, 2021. ORIC-101 is part of two Phase 1b trials addressing therapeutic resistance in cancer. The call will feature insights from Professor Pamela Munster, a key investigator.
ORIC Pharmaceuticals reported its financial results for Q1 2021, highlighting progress in its oncology pipeline. The lead program, ORIC-101, is on track for Phase 1b data readouts in 2021, with two abstracts accepted for presentation at the ASCO Annual Meeting. The company anticipates filing INDs for ORIC-533, ORIC-944, and ORIC-114 within the year. Financially, cash and equivalents totaled $278.1 million, expected to fund operations through mid-2023. R&D expenses rose to $11.7 million, primarily due to advancements in product candidates, while G&A expenses increased to $4.9 million.
